NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $331,692 | -29.3% | 42,200 | -10.1% | 0.00% | – |
| Q2 2023 | $469,130 | -53.3% | 46,960 | -58.5% | 0.00% | -100.0% |
| Q1 2023 | $1,004,364 | +24.3% | 113,104 | +53.7% | 0.00% | 0.0% |
| Q4 2022 | $808,084 | -48.5% | 73,596 | -38.9% | 0.00% | 0.0% |
| Q3 2022 | $1,570,000 | +64.6% | 120,518 | +60.1% | 0.00% | 0.0% |
| Q2 2022 | $954,000 | +170.3% | 75,265 | +198.9% | 0.00% | – |
| Q1 2022 | $353,000 | -84.1% | 25,180 | -67.1% | 0.00% | -100.0% |
| Q4 2021 | $2,218,000 | -38.6% | 76,611 | -36.5% | 0.00% | -50.0% |
| Q3 2021 | $3,615,000 | +11.2% | 120,652 | -1.5% | 0.00% | 0.0% |
| Q2 2021 | $3,250,000 | +23.3% | 122,511 | +44.5% | 0.00% | 0.0% |
| Q1 2021 | $2,635,000 | +2171.6% | 84,756 | +2312.0% | 0.00% | – |
| Q4 2020 | $116,000 | +510.5% | 3,514 | +559.3% | 0.00% | – |
| Q3 2020 | $19,000 | – | 533 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |